Immutep LtdASX: IMM

Webcast to discuss data presented at ESMO Plenary Session

· Issued by Immutep Ltd

Filed with ASX · · 15 pages · English

Summary by 6ix AI

The presentation highlights the complementary effects of Efti with KEYTRUDA and reports on the trial's design, patient demographics, and treatment outcomes. Key findings include a significant tumor response rate and a strong safety profile, indicating promising results for a chemo-free regimen in this patient population. The company outlines future milestones and catalysts, including updates on various cancer studies and a solid cash balance to support ongoing operations.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Immutep Ltd on 6ix

In the deck

Earlier from Immutep

Later from Immutep

All Immutep news releases